Dr. Mireia Pelegrin obtained her Veterinary degree in Barcelona before pursuing a PhD at the Autonomous University of Barcelona, where her research focused on developing transgenic mice as models for diabetes.

Following her doctoral studies, she moved to France for postdoctoral training at the Institute of Molecular Genetics of Montpellier. During this time, her work centered on developing gene and cell therapy approaches for the in vivo production of therapeutic monoclonal antibodies (mAbs), a project that resulted in two international patents.

In 2000, Dr. Pelegrin joined the CNRS as a Senior Researcher at the same institute, leading a research program in antiviral immunotherapies.

In 2019, she moved to the Institute for Regenerative Medicine and Biotherapies of Montpellier, where she currently heads the "Antibodies and Immunomodulation" group. Dr. Pelegrin has extensive experience in studying host-pathogen interactions and antiviral immunotherapies. Notably, she pioneered the proof-of-concept that mAb-based immunotherapies can induce long-term protective adaptive immune responses, exhibiting vaccine-like effects.

She has published over 40 articles in the fields of immunovirology and antiviral immunotherapies.

Her current research focuses on developing innovative immunotherapies based on mAbs, antibody-derived molecules, and cell therapies including CAR-T cells, as well as deciphering and harnessing antibody-mediated immunomodulation mechanisms for therapeutic strategies.

Dr. Mireia Pelegrin